Cargando…

Breast cancer in young women: prevalence of LOH at p53, BRCA1 and BRCA2

Detalles Bibliográficos
Autores principales:	Johnson, SM, Shaw, JA, Walker, RA
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2000
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3300897/ http://dx.doi.org/10.1186/bcr96

Ejemplares similares

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

Germline BRCA2 and somatic P53 alterations in male breast cancer
por: Csokay, B, et al.
Publicado: (2000)

Mutational analysis of BRCA1 and BRCA2 genes in Spanish women with early-onset breast cancer
por: Martínez-Ferrandis, JI, et al.
Publicado: (2000)

P53 mutations in breast and ovarian carcinomas from BRCA1 and 2 mutation carriers and noncarriers
por: Sensi, E, et al.
Publicado: (2000)

Expression profiling of BRCA1 associated breast tumors
por: Berns, EMJJ, et al.
Publicado: (2000)

Large genomic rearrangements in BRCA1 and BRCA2 genes in breast and ovarian cancer families in Poland
por: Bielecka, Helena, et al.
Publicado: (2012)

Large genomic rearrangements in BRCA1 and BRCA2 genes in breast and ovarian cancer families in Poland
por: Bielecka, Helena, et al.
Publicado: (2012)

Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
por: Byrski, T, et al.
Publicado: (2011)

Association of tamoxifen use and reduced risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers
por: Phillips, KA, et al.
Publicado: (2012)

Embryonic lethality in the Brca1-1700T mouse model suggests inhibition of p53-dependent pathways
por: Hohenstein, P, et al.
Publicado: (2000)

Haplotype analysis in German families with recurrent BRCA1 and BRCA2 mutations
por: Wappenschmidt, B, et al.
Publicado: (2001)

Cisplatin in breast cancer treatment in BRCA1 carriers
por: Gronwald, Jacek, et al.
Publicado: (2012)

BRCA1, BRCA2 and pedigree genetic analysis to determine genetic risk in the UK Royal Marsden Hospital tamoxifen prevention trial
por: Kote-Jarai, Z, et al.
Publicado: (2000)

BRCA2 interacting proteins
por: Vidarsson, H, et al.
Publicado: (2000)

BRCA1 testing in Lithuania
por: Janavicius, Ramunas
Publicado: (2012)

Molecular characterization of BRCA1 and BRCA2 genes in breast cancer patients under 40 years-old or with familiar cancer history
por: Millan, Silvia Vidal, et al.
Publicado: (2007)

The contribution of LARGE genomic rearrangements of BRCA1 and BRCA2 gene mutations in breast and ovarian cancer families in a clinical cohort
por: Sawyer, S, et al.
Publicado: (2012)

BRCA1 mutation in the Triple- Negative Breast Cancer Group
por: Maksimenko, Jelena, et al.
Publicado: (2012)

Constitutional alterations of 9p23-24 in independent BRCA2 breast cancer families
por: Schwab, M, et al.
Publicado: (2000)

Germline mutations of BRCA1-associated RING domain (BARD1) gene in breast and/or ovarian families negative for BRCA1 and 2 alterations
por: Ghimenti, C, et al.
Publicado: (2000)

Estrogen receptor transcription and transactivation: Genetic modifiers of cancer risks conferred by BRCA1 and BRCA2
por: Devilee, P
Publicado: (2001)

Searching for BRCA3 by exome sequencing
por: Makunin, I, et al.
Publicado: (2012)

Role of the breast cancer susceptibility gene BRCA1 in radio-resistance
por: Sylvain, V, et al.
Publicado: (2000)

Why choose the treatment with cisplatin for BRCA1 breast cancers patients?
por: Byrski, T, et al.
Publicado: (2012)

A multi-center study to evaluate the impact of germline BRCA1 and BRCA2 mutations on ovarian cancer survival
por: Bolton, KL, et al.
Publicado: (2012)

BRCA1 mutation analysis in breast and ovarian cancer families from Greece
por: Konstantopoulou, I, et al.
Publicado: (2000)

Impact of BRCA1 mutation on survival after early onset breast cancer
por: Huzarski, T, et al.
Publicado: (2012)

Selenium and the risk of cancer in BRCA1 carriers
por: Lubinski, J, et al.
Publicado: (2011)

When, how and why BRCA1 and BRCA2 genetic testing is offered to patients who do not meet standard criteria
por: Duffy, J, et al.
Publicado: (2012)

What are the unmet support needs of women with a known BRCA1/2 mutation?
por: White, V, et al.
Publicado: (2012)

Mammary-specific targeting of the murine BRCA2 breast cancer susceptibility gene in mice
por: Collins, NK, et al.
Publicado: (2000)

Pathological complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients
por: Byrski, Tomasz, et al.
Publicado: (2015)

BRCA1 mutation- oncological treatment- reconstructive surgery of the breast- pregnancy: diagnostic and therapeutic procedures in a 28 year old patient diagnosed with a tumor in the left breast with a BRCA1 mutation
por: Kilar, Ewa
Publicado: (2012)

Constitutional genomic instability of 9p23-24 in BRCA2 mutation carriers
por: Savelyeva, L, et al.
Publicado: (2001)

Folic acid and cancer risk in BRCA1 carriers
por: Durda, Katarzyna, et al.
Publicado: (2012)

BRCA1 founder mutations and ovarian cancer in Belarus
por: Savanevich, A, et al.
Publicado: (2015)

Mutations of the BRCA1 and BRCA2 Genes in Danish Patients Diagnosed at Young Age with Multi-Centric or Bilateral Breast Cancer
por: Bergthorsson, J. T., et al.
Publicado: (1999)

Selenium and genotypes as marker of risk in BRCA1 mutation carriers
por: Jaworska, K, et al.
Publicado: (2012)

Chromosomal instability and cancer predisposition: insights from studies on the breast cancer susceptibility gene BRCA2
por: Venkitaraman, A
Publicado: (2001)

One test to identify 50% of all Norwegian BRCA1 mutations
por: Møller, P, et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_1m1gu0njmnldjdv95a27pop4hv